Physician

Douglas J Kemme, MD

According to 2025 Medicare claims, Douglas Kemme, MD (NPI: 1568414621) practices hematology/oncology in the Greeley, CO market, with the plurality of this provider's patient population coming from Weld, CO. This provider's primary affiliated billing organization is POUDRE VALLEY MEDICAL GROUP, LLC (NPI: 1366763260; TIN: 800348943) and primary practice location at 80634-5474. Kemme is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604) and Banner Network Colorado, LLC (ACO ID: A4768), participating under the MSSP model.

Kemme's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 464 traditional Medicare patients, billed 1,992 HCPCS/CPT codes, and received $96,777 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,653 prescription claims across 287 beneficiaries totaling $4,642,030 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 82 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,000,772 to $4,642,030. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $25,673 to $772.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	466	1,170	$70,278
2016	502	1,192	$73,013
2017	526	1,376	$86,462
2018	602	1,389	$78,838
2019	538	1,415	$77,389
2020	447	1,268	$76,015
2021	487	1,158	$91,928
2022	497	1,022	$80,963
2023	497	1,287	$87,697
2024	464	1,992	$96,777

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	208	1,179	$1,000,772
2016	211	968	$1,001,548
2017	207	1,043	$730,661
2018	224	1,084	$1,427,416
2019	223	1,202	$1,876,959
2020	240	1,357	$2,225,107
2021	278	1,701	$3,534,690
2022	299	1,598	$3,338,946
2023	271	1,487	$2,792,717
2024	287	1,653	$4,642,030

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	49	345	$110,456
2016	32	323	$85,285
2017	N/R	183	$26,378
2018	N/R	105	$12,124
2019	N/R	69	$7,659
2020	11	120	$8,341
2021	24	160	$10,665
2022	22	87	$3,732
2023	24	182	$51,041
2024	N/R	82	$1,970

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	46	46	$133
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	122	170	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	297	552	$75
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	176	203	$50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	418	817	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	39	1,170	$639,829
Revlimid	Lenalidomide	35	980	$619,264
Xtandi	Enzalutamide	38	1,140	$557,998
Pomalyst	Pomalidomide	23	644	$508,061
Calquence	Acalabrutinib Maleate	30	900	$336,064

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	29	$877
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$478
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$376
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	21	$238

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Douglas J. Kemme, MD?

Tedicare shows public-source Medicare data for Douglas J. Kemme, MD (NPI 1568414621), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Douglas J. Kemme, MD have ACO affiliation data?

Douglas J. Kemme, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604) and Banner Network Colorado, LLC (MSSP, ACO ID A4768).

What billing organization is linked to Douglas J. Kemme, MD?

Douglas J. Kemme, MD is linked to POUDRE VALLEY MEDICAL GROUP, LLC (billing NPI 1366763260) in the available physician profile data.

Does Douglas J. Kemme, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.